18.20
-0.56(-2.99%)
Currency In USD
| Previous Close | 18.76 |
| Open | 18.9 |
| Day High | 19.18 |
| Day Low | 18.18 |
| 52-Week High | 22.68 |
| 52-Week Low | 7.8 |
| Volume | 695,818 |
| Average Volume | 665,582 |
| Market Cap | 996.99M |
| PE | 3.38 |
| EPS | 5.38 |
| Moving Average 50 Days | 16.62 |
| Moving Average 200 Days | 13.04 |
| Change | -0.56 |
If you invested $1000 in Bicara Therapeutics Inc. Common Stock (BCAX) since IPO date, it would be worth $777.45 as of December 06, 2025 at a share price of $18.2. Whereas If you bought $1000 worth of Bicara Therapeutics Inc. Common Stock (BCAX) shares 6 months ago, it would be worth $1,582.61 as of December 06, 2025 at a share price of $18.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
GlobeNewswire Inc.
6 hours ago
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study interim analysis Totality of data demonstrates tha
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates overall response rate and safety profile consistent with the 1500mg QW dose Data inform and advance progress toward dose selection for ongoing pivotal FORTIFI-HN01 clinical trial
Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
GlobeNewswire Inc.
Oct 13, 2025 11:30 AM GMT
Designation supported by results from multiple dose cohorts from the Phase 1/1b trial of ficerafusp alfa in 1L HPV-negative R/M HNSCCBOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutic